An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities

被引：13

作者：

Pan, Ziyan ^{[1
,2
]}

Fan, Jian-Gao ^{[3
]}

Eslam, Mohammed ^{[1
,2
]}

机构：

[1] Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Sydney, NSW 2145, Australia

[2] Univ Sydney, Sydney, NSW 2145, Australia

[3] Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med,Ctr Fatty Liver,Dept Gastroenterol, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai, Peoples R China

来源：

CURRENT OPINION IN PHARMACOLOGY | 2021年 / 60卷

基金：

英国医学研究理事会; 中国国家自然科学基金;

关键词：

NONALCOHOLIC STEATOHEPATITIS; OBETICHOLIC ACID; FIBROSIS; AGONIST; NAFLD; NASH; REDEFINITION; TROPIFEXOR; ARAMCHOL;

D O I：

10.1016/j.coph.2021.07.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Despite the rising health burden of metabolic (dysfunction) associated fatty liver disease (MAFLD), there are no approved pharmacotherapies for MAFLD currently. This situation led to a significant escalation in drug development and randomized controlled trials for MAFLD, particularly as novel information about its molecular pathogenesis unfolds. Currently, there are numerous investigational candidate drugs for MAFLD in various stages of clinical development that act on different pathophysiological processes, such as metabolism/steatosis, inflammation or fibrosis. Here, we provide an update on drug development for the treatment of MAFLD and discuss the prospects and challenges for improving and accelerating the nonalcoholic fatty liver disease drug discovery pipeline.

引用

页码：170 / 176

页数：7

共 66 条

[1] The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].

Adams, LA ;

Lymp, JF ;

St Sauver, J ;

Sanderson, SO ;

Lindor, KD ;

Feldstein, A ;

Angulo, P .

GASTROENTEROLOGY, 2005, 129 (01) :113-121

[2]

Ampuero J, 2021, REV ESP ENFERM DIG

[3] Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects [J].

Ampuero, Javier ;

Aller, Rocio ;

Gallego-Duran, Rocio ;

Crespo, Javier ;

Abad, Javier ;

Gonzalez-Rodriguez, Agueda ;

Gomez-Camarero, Judith ;

Caballeria, Joan ;

Lo Iacono, Oreste ;

Ibanez, Luis ;

Garcia-Samaniego, Javier ;

Martin-Mateos, Rosa ;

Frances, Ruben ;

Fernandez-Rodriguez, Conrado ;

Diago, Moises ;

Soriano, German ;

Andrade, Raul J. ;

Latorre, Raquel ;

Jorquera, Francisco ;

Morillas, Rosa M. ;

Escudero, Desam ;

Estevez, Pamela ;

Hernandez-Guerra, Manuel ;

Augustin, Salvador ;

Pareja-Megia, Maria Jesus ;

Banales, Jesus M. ;

Aspichueta, Patricia ;

Benlloch, Salvador ;

Rosales, Jose Miguel ;

Salmeron, Javier ;

Turnes, Juan ;

Romero-Gomez, Manuel .

LIVER INTERNATIONAL, 2021, 41 (09) :2076-2086

[4] The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].

Angulo, Paul ;

Hui, Jason M. ;

Marchesini, Giulio ;

Bugianesi, Ellisabetta ;

George, Jacob ;

Farrell, Geoffrey C. ;

Enders, Felicity ;

Saksena, Sushma ;

Burt, Alastair D. ;

Bida, John P. ;

Lindor, Keith ;

Sanderson, Schuyler O. ;

Lenzi, Marco ;

Adams, Leon A. ;

Kench, James ;

Therneau, Terry M. ;

Day, Christopher P. .

HEPATOLOGY, 2007, 45 (04) :846-854

[5]

[Anonymous], 2020, ALBIREO PHARMA ALBO

[6] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[7] The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease [J].

Bayoumi, Ali ;

Gronbaek, Henning ;

George, Jacob ;

Eslam, Mohammed .

TRENDS IN GENETICS, 2020, 36 (06) :429-441

[8] Adaptive Designs for Clinical Trials [J].

Bhatt, Deepak L. ;

Mehta, Cyrus .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (01) :65-74

[9] NAFLD: A multisystem disease [J].

Byrne, Christopher D. ;

Targher, Giovanni .

JOURNAL OF HEPATOLOGY, 2015, 62 :S47-S64

[10] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Charlton, Michael ;

Cusi, Kenneth ;

Rinella, Mary ;

Harrison, Stephen A. ;

Brunt, Elizabeth M. ;

Sanyal, Arun J. .

HEPATOLOGY, 2018, 67 (01) :328-357

← 1 2 3 4 5 6 7 →